In the latest trading session, 2.28 million Esperion Therapeutics Inc (NASDAQ:ESPR) shares changed hands as the company’s beta touched 1.01. With the company’s most recent per share price at $2.20 changed hands at -$0.14 or -6.11% at last look, the market valuation stands at $432.88M. ESPR’s current price is a discount, trading about -79.09% off its 52-week high of $3.94. The share price had its 52-week low at $1.58, which suggests the last value was 28.18% up since then. When we look at Esperion Therapeutics Inc’s average trading volume, we note the 10-day average is 4.2 million shares, with the 3-month average coming to 5.76 million.
Analysts gave the Esperion Therapeutics Inc (ESPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.78. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ESPR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Esperion Therapeutics Inc’s EPS for the current quarter is expected to be -0.13.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Instantly ESPR was in red as seen in intraday trades today. With action 0.32%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -0.14%, with the 5-day performance at 0.32% in the green. However, in the 30-day time frame, Esperion Therapeutics Inc (NASDAQ:ESPR) is -27.73% down. Looking at the short shares, we see there were 25.47 million shares sold at short interest cover period of 3.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 72.5% from its recent market value. According to analyst projections, ESPR’s forecast low is 8 with 8 as the target high. To hit the forecast high, the stock’s price needs a -263.64% plunge from its current level, while the stock would need to soar -263.64% for it to hit the projected low.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
Data shows that the Esperion Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -12.47% over the past 6 months, a 86.70% in annual growth rate that is considerably higher than the industry average of 16.20%. Year-over-year growth is forecast to reach 180.41% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 63.06M. 3 analysts are of the opinion that Esperion Therapeutics Inc’s revenue for the current quarter will be 53.3M. The company’s revenue for the corresponding quarters a year ago was 32.25M and 137.74M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 95.53%. The estimates for the next quarter sales put growth at -61.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 23.09%. The 2025 estimates are for Esperion Therapeutics Inc earnings to increase by 85.06%.
ESPR Dividends
Esperion Therapeutics Inc is expected to release its next quarterly earnings report in February.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.48% of Esperion Therapeutics Inc shares while 65.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 66.31%. There are 65.99% institutions holding the Esperion Therapeutics Inc stock share, with WASATCH ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 9.9628% of the shares, roughly 16.86 million ESPR shares worth $37.44 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.2617% or 13.98 million shares worth $31.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. With 6.68 shares estimated at $14.55 million under it, the former controlled 3.39% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.14% of the shares, roughly 6.18 shares worth around $13.47 million.
